Eurofins-Cerep (XPAR:ALECR) GF Score: 27/100 (As of Aug. 16, 2026) — 29% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XPAR:ALECR Eurofins-Cerep SA XPAR:ALECR
27 GF Score
Price €16,300.00
GF Value €20,317.48
! 4 Warning Signs
View Full Analysis

What is Eurofins-Cerep GF Score?

Eurofins-Cerep XPAR:ALECR 27 GF Score is 27 as of Aug. 16, 2026, which is 29% below its 10-year median of 38.00. GuruFocus rates XPAR:ALECR with a GF Score™ of 27/100 and a GF Value™ of €20,317.48. The stock has 4 warning signs investors should review.

Eurofins-Cerep has the GF Score of 27, which implies that the company might have Worst future performance potential, or not enough data.

The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.

GF Score takes following five key aspects into consideration:

1. Financial Strength : 10/10
2. Profitability Rank : 8/10
3. Growth Rank : 0/10
4. GF Value Rank : 10/10
5. Momentum Rank : 0/10

Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.

Based on research and backtesting result, GuruFocus believes Eurofins-Cerep might have Worst future performance potential, or not enough data.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Eurofins-Cerep  (XPAR:ALECR) GF Score Explanation

Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:

GF Score Performance Potential and All-in-One Screener Examples (1)
91 - 100Highest outperformance potential
81 - 90Good outperformance potential
71 - 80Likely to have average performance
51 - 70Poor future performance potential
0 - 50Worst future performance potential, or not enough data

(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.

Eurofins-Cerep GF Score Related Terms

XPAR:ALECR vs TMO, DHR, IDXX: GF Score Comparison

For the Diagnostics & Research subindustry, Eurofins-Cerep's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Eurofins-Cerep GF Score vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Eurofins-Cerep's GF Score distribution charts can be found below:

* The bar in red indicates where Eurofins-Cerep's GF Score falls into.


XPAR:ALECR
27GF Score
Eurofins-Cerep SA XPAR:ALECR
GF Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about GF Score →
What does a GF Score of 27 mean?
Eurofins-Cerep (XPAR:ALECR) has a GF Score of 27 as of Aug. 16, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Eurofins-Cerep and its competitors. This is 29% below median its historical median of 38.00. Over the past decade, Eurofins-Cerep's GF Score has ranged from 11.00 to 83.00.
Is Eurofins-Cerep's GF Score too high?
Eurofins-Cerep's current GF Score of 27 is 29% below median its 10-year median of 38.00. Over the past 10 years, this metric has ranged from a low of 11.00 to a high of 83.00. Overall, Eurofins-Cerep has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Eurofins-Cerep's GF Score compare to TMO and DHR?
Eurofins-Cerep's GF Score of 27 can be compared against companies in the Medical Diagnostics & Research industry. Historically, Eurofins-Cerep's own GF Score has ranged from 11.00 to 83.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Medical Diagnostics & Research company?
A good GF Score depends on the Medical Diagnostics & Research industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Eurofins-Cerep and its competitors. Eurofins-Cerep's current GF Score is 27, which is 29% below median its own 10-year median of 38.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eurofins-Cerep stock overvalued right now?
Eurofins-Cerep (XPAR:ALECR) has a current GF Score of 27. The stock's GF Value™ is €20,317.48, compared to a current price of €16,300.00 — trading 19.8% below its estimated fair value. The current GF Score is 27, which is 29% below median its 10-year median of 38.00. Eurofins-Cerep's overall GF Score™ is 27/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For Eurofins-Cerep (XPAR:ALECR), the current GF Score is 27 as of Aug. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Eurofins-Cerep (XPAR:ALECR) Overvalued in 2026?

Based on GuruFocus' analysis, Eurofins-Cerep stock appears to be undervalued. The current stock price of €16,300.00 is trading 19.8% below its estimated GF Value™ of €20,317.48.

Key valuation signals for XPAR:ALECR:

  • GF Score: 27 (29% below median its 10-year median of 38.00)
  • GF Value™: €20,317.48 vs. price of €16,300.00 (19.8% below fair value)
  • GF Score™: 27/100 with 4 warning signs

No single metric tells the full story. See the XPAR:ALECR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Eurofins-Cerep Business Description

Address Le bois l Eveque, Celle l Evescault, FRA, 86600
Eurofins-Cerep SA provides in vitro pharmacology, in vitro ADME-Tox and in vivo PK services and solutions. The company also offers cost-effective drug discovery by identifying at early stages drug candidates and eliminating them. Some solutions provided by the company are - compound management, high-throughout screening, in vitro safety profiling, lead optimization profiling, in vitro ADME profiling, and in vivo PK.
27GF Score

Get the complete analysis for XPAR:ALECR

GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€16,300.00
Price
€20,317.48
GF Value